I-Mab Salute del bilancio

Salute finanziaria criteri di controllo 4/6

I-Mab ha un patrimonio netto totale di $236.6M e un debito totale di $4.0M, che porta il suo rapporto debito/patrimonio netto a 1.7%. Le sue attività totali e le sue passività totali sono rispettivamente $253.8M e $17.2M.

Informazioni chiave

1.7%

Rapporto debito/patrimonio netto

US$3.96m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$207.49m
Patrimonio netto	US$236.63m
Totale passività	US$17.19m
Totale attività	US$253.83m

Aggiornamenti recenti sulla salute finanziaria

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Feb 08

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

Recent updates

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Sep 13

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

Aug 30

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Aug 23

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 20

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

Jul 22

I-Mab Valuation Offers A Biotech Investment Opportunity

Jun 23

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

May 06

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Apr 01

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Jan 03

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

Oct 14

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $230.5M ) di IMAB superano le sue passività a breve termine ( $14.0M ).

Passività a lungo termine: Le attività a breve termine di IMAB ( $230.5M ) superano le sue passività a lungo termine ( $3.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: IMAB ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di IMAB si è ridotto da 9.3% a 1.7% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: Dati insufficienti per determinare se IMAB ha una pista di cassa sufficiente in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Dati insufficienti per determinare se IMAB ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

Scoprire le aziende sane

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/02/16 15:59
Prezzo dell'azione a fine giornata	2025/02/14 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

I-Mab è coperta da 19 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Bo Li	BofA Global Research
Louise Chen	Cantor Fitzgerald & Co.
Ziyu He	China International Capital Corporation Limited

I-Mab Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

Recent updates

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Consensus revenue estimates fall by 63%

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

Price target decreased to US$74.89

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest

Consensus revenue estimates fall by 32%

Price target decreased to US$87.94

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Founder notifies of intention to sell stock

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors